RPG Life Sciences vs Senores Pharma vs Rubicon Research: Which Stock Should You Track
- October 6, 2026
- Posted by: Neeraj Pandey
- Category: Market
RPG Life Sciences PE 39.98, mkt cap Rs 4,784 crore. Senores Pharmaceuticals PE 46.56, mkt cap Rs 6,092 crore. Rubicon Research PE 92.46, mkt cap Rs 26,645 crore.
Quick Answer
RPG Life Sciences vs Senores Pharmaceuticals vs Rubicon Research is a side-by-side comparison of three companies from the Pharma and Life Sciences space. On this comparison, RPG Life Sciences carries a market capitalisation of about Rs 4,784 crore against Rs 6,092 crore for Senores Pharmaceuticals and Rs 26,645 crore for Rubicon Research, with return on equity of 19.03%, 12.36% and 19.14% respectively. Each company’s numbers are presented here without a declared better pick, since the right stock depends on an investor’s own criteria.
RPG Life Sciences vs Senores Pharmaceuticals vs Rubicon Research starts with the core numbers most investors compare within the Pharma and Life Sciences segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.
All three names sit in the Pharma and Life Sciences bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.
Click Here – Get Free Investment Predictions
RPG Life Sciences, Senores Pharmaceuticals and Rubicon Research: Company Overview
RPG Life Sciences is a listed Indian company in the Pharma and Life Sciences space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Senores Pharmaceuticals is a listed Indian company in the Pharma and Life Sciences space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
Rubicon Research is a listed Indian company in the Pharma and Life Sciences space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.
RPG Life Sciences vs Senores Pharmaceuticals vs Rubicon Research: Valuation and Profitability Snapshot
| Metric | RPG Life Sciences | Senores Pharmaceuticals | Rubicon Research |
|---|---|---|---|
| Market Cap (approx.) | Rs 4,784 crore | Rs 6,092 crore | Rs 26,645 crore |
| PE Ratio (TTM) | 39.98 | 46.56 | 92.46 |
| PB Ratio | 7.90 | 6.52 | 20.67 |
| Return on Equity (ROE) | 19.03% | 12.36% | 19.14% |
| EPS (TTM, Rs) | 72.34 | 28.41 | 17.41 |
| Dividend Yield | 0.83% | 0.00% | 0.09% |
| Debt to Equity | 0.03 | 0.37 | 0.24 |
| Book Value per Share (Rs) | 366.01 | 202.72 | 77.86 |
Check the Univest Screener for Live Data
On valuation, RPG Life Sciences trades at a PE of 39.98 and a PB of 7.90, Senores Pharmaceuticals at a PE of 46.56 and a PB of 6.52, while Rubicon Research trades at a PE of 92.46 and a PB of 20.67. On return on equity, the three post 19.03%, 12.36% and 19.14% respectively, and on dividend yield they stand at 0.83%, 0.00% and 0.09%.
RPG Life Sciences vs Senores Pharmaceuticals vs Rubicon Research: Latest Quarterly Results
| Company | Latest Quarter Revenue | Latest Quarter Net Profit | YoY Change (Revenue) | QoQ Change (Revenue) |
|---|---|---|---|---|
| RPG Life Sciences | Rs 200.39 crore | Rs 30.76 crore | +15.1% | +5.9% |
| Senores Pharmaceuticals | Rs 183.02 crore | Rs 30.45 crore | +24.7% | -5.1% |
| Rubicon Research | Rs 540.02 crore | Rs 84.78 crore | +52.9% | +4.5% |
Quarterly figures above are the most recent reported quarter for each company (Q1 FY27, quarter ended June 2026), compared with the year-ago and preceding quarter.
Download the Univest iOS App or Univest Android App to track RPG Life Sciences, Senores Pharmaceuticals and Rubicon Research live prices.
What Should Investors Look at Beyond These Numbers?
Beyond the metrics above, investors comparing these three pharma and life sciences names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.
Conclusion
RPG Life Sciences vs Senores Pharmaceuticals vs Rubicon Research highlights how differently three companies in the same pharma and life sciences segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information as of September 2026 and may not reflect real-time prices. Please verify all data independently before making any investment decision. This comparison does not recommend or endorse any single stock over another; investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on RPG Life Sciences vs Senores Pharmaceuticals vs Rubicon Research
What is the market cap difference between RPG Life Sciences, Senores Pharmaceuticals and Rubicon Research?
Ans. As of September 2026, RPG Life Sciences has a market cap of approximately Rs 4,784 crore, Senores Pharmaceuticals is at approximately Rs 6,092 crore, and Rubicon Research is at approximately Rs 26,645 crore.
Which of the three has the highest PE ratio?
Ans. Among RPG Life Sciences, Senores Pharmaceuticals and Rubicon Research, the PE ratios stand at 39.98, 46.56 and 92.46 respectively as of September 2026.
Which of the three has the highest ROE?
Ans. RPG Life Sciences, Senores Pharmaceuticals and Rubicon Research post ROE of 19.03%, 12.36% and 19.14% respectively as of September 2026.
Which of these three stocks pays the highest dividend yield?
Ans. RPG Life Sciences, Senores Pharmaceuticals and Rubicon Research carry dividend yields of 0.83%, 0.00% and 0.09% respectively.
What is the debt to equity ratio for RPG Life Sciences, Senores Pharmaceuticals and Rubicon Research?
Ans. RPG Life Sciences carries a debt to equity of 0.03, Senores Pharmaceuticals of 0.37, and Rubicon Research of 0.24.
Which of the three trades at the highest price to book value?
Ans. RPG Life Sciences, Senores Pharmaceuticals and Rubicon Research trade at price to book ratios of 7.90, 6.52 and 20.67 respectively.
Is one of RPG Life Sciences, Senores Pharmaceuticals or Rubicon Research better than the others?
Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor’s own criteria and research.
